Celeris Therapeutics
Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (CelerisTx One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices.CelerisTx's drug pipeline is focused on CNS and oncology, targeting unmet medical needs. We also co-develop therapeutics with pharmaceutical and biotech companies. CelerisTx has so far attracted a total of EUR 18 million in committed capital from venture capital funds, which include EIC Fund, Pace Ventures Enigma, i&i biotech, Apex Ventures, R42 and longevitytech.fund.#targetedproteindegradation #degrader #ubiquitinproteasomesystem #machinelearning #CelerisOne #proximityinducingcompounds #PICs
Company Overview
Celeris Therapeutics is a public company established in 2021, specializing in the pharmaceutical manufacturing industry. The company operates with a small team of 24 employees and is headquartered in Menlo Park, California, with an additional location in Graz, Austria. Celeris Therapeutics focuses on leveraging advanced technologies, particularly deep learning and artificial intelligence, to enhance drug discovery and design processes.
Specialties and Technologies
Celeris Therapeutics has developed expertise in various areas, including deep learning, geometric deep learning, protein-protein interactions (PPI), and protein-ligand interactions. The company specializes in innovative drug design methodologies such as PROTAC and molecular glue. Its proprietary CelerisTx One™ platform serves as a closed-loop engine for AI-driven protein-interaction complex (PIC) design, facilitating the development of therapeutics.
Focus Areas
Celeris Therapeutics concentrates its drug pipeline on addressing central nervous system (CNS) disorders and oncology. The company aims to tackle unmet medical needs in these areas by utilizing its advanced technological capabilities and collaborative efforts with pharmaceutical and biotech companies. This focus reflects the company's commitment to improving patient outcomes through innovative therapeutic solutions.
Funding and Investment
Celeris Therapeutics has successfully attracted a total of EUR 18 million in committed capital from various venture capital funds. Notable investors include EIC Fund, Pace Ventures Enigma, i&i biotech, Apex Ventures, R42, and longevitytech.fund. This financial backing supports the company's research and development initiatives, enabling it to advance its drug discovery and design efforts.
Collaborative Development
Celeris Therapeutics engages in co-development of therapeutics in partnership with other pharmaceutical and biotech companies. This collaborative approach allows the company to leverage external expertise and resources, enhancing its capabilities in drug discovery and development. By working together with industry partners, Celeris Therapeutics aims to accelerate the delivery of innovative treatments to the market.